Remove 2024 Remove Communication Remove Documentation
article thumbnail

FDA Publishes Its Draft Strategy Document on Innovative Manufacturing Technologies

FDA Law Blog: Biosimilars

FDA-2024-N-3945 ] announcing the publication of a draft strategy document, for public comment, outlining specific actions FDA plans to take to facilitate the use of innovative manufacturing technologies. It was at this workshop that the agency committed to issuing a draft strategy document, for public comment.

article thumbnail

Medical Writing in Enhancing Healthcare Communication

Viseven

It’s like a bridge connecting the intricate world of medical science to everyday healthcare communication. As a specialized field, medical writing encompasses the creation of various documents, from regulatory submission documents to medical journal articles, that convey critical medical knowledge to diverse audiences.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

FDA Updates Draft Guidance on Promotional Communications of Prescription Biologics and Biosimilars

Big Molecule Watch

The updated guidance includes information on the general requirements for the content of FDA-regulated promotional communications about reference or biosimilar products and provides some examples to illustrate the FDA’s current recommendations for addressing reference, biosimilar, and interchangeable biosimilar products in product promotion.

article thumbnail

NHC Comments on Medicare Advantage and Prescription Drug Programs: Part C and Part D Medicare Prescription Payment Plan Model Documents (CMS-10882) – IRA

Putting Patients First Blog

Other members include health-related associations and nonprofit organizations including the provider, research, and family caregiver communities; and businesses and organizations representing biopharmaceuticals, devices, diagnostics, generics, and payers.

article thumbnail

NHC Comments on Medicare Advantage and Prescription Drug Programs: Part C and Part D Medicare Prescription Payment Plan Model Documents

Putting Patients First Blog

Recognizing both the potential benefits and challenges of the MPPP rollout, the NHC views the introduction of these documents as crucial for educating beneficiaries on their options, easing transitions, and possibly lessening the financial impact of prescription costs.

article thumbnail

State of Well-Being 2023-2024

The Happy PharmD

The stress experienced by community pharmacists compared to those in other settings is well-documented and has been a longstanding issue. A cultural shift within the profession is also needed, encouraging open communication and prioritizing self-care to create a supportive environment for pharmacists.

article thumbnail

FOPE and Pharma State Academy focus on Quality Risk Management in latest PULSE session

Express Pharma

FOPE and Pharma State Academy recently hosted, third session of their PULSE series on August 11, 2024, spotlighting “Quality Risk Management (QRM)” with a special focus on the Revised Schedule M. The panel also discussed the differences between ICH Q9 and the Revised Schedule M, and the importance of meticulous documentation.